Site-Specific Oxidation of (sp<sup>3</sup>)C–C(sp<sup>3</sup>)/H Bonds by NaNO<sub>2</sub>/HCl
作者:Jianyou Zhao、Tong Shen、Zhihui Sun、Nengyong Wang、Le Yang、Jintao Wu、Huichao You、Zhong-Quan Liu
DOI:10.1021/acs.orglett.1c01303
日期:2021.5.21
(sp3)C–C(sp3) and (sp3)C–H bonds in aryl alkanes by the use of NaNO2/HCl was explored. The method is chemical-oxidant-free, transition-metal-free, uses water as the solvent, and proceeds under mild conditions, making it valuable and attractive to syntheticorganicchemistry.
Electrochemical Aerobic Oxidative Cleavage of (sp<sup>3</sup>)C–C(sp<sup>3</sup>)/H Bonds in Alkylarenes
作者:Tong Shen、Shuai Liu、Jianyou Zhao、Nengyong Wang、Le Yang、Jintao Wu、Xu Shen、Zhong-Quan Liu
DOI:10.1021/acs.joc.1c02947
日期:2022.3.4
An electrochemistry-promoted oxidativecleavage of (sp3)C–C(sp3)/Hbonds in alkylarenes was developed. Various aryl alkanes can be smoothly converted into ketones/aldehydes under aerobic conditions using a user-friendly undivided cell setup. The features of air as oxidant, scalability, and mild conditions make them attractive in synthetic organic chemistry.
The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
[EN] NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS<br/>[FR] NOUVEAUX COMPOSES DE RETINOIDE TRIENOIQUE ET METHODES D'UTILISATION
申请人:LIGAND PHARMACEUTICALS INCORPORATED
公开号:WO1996020913A1
公开(公告)日:1996-07-11
(EN) Novel trienoic retinoid compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.(FR) L'invention porte sur des composés de rétinoïde triénoïque faisant preuve d'activité à l'égard de récepteurs d'acide rétinoïque et de récepteurs de rétinoïde X. Elle porte également sur des préparations pharmaceutiques contenant ces composés ainsi que sur leurs méthodes d'utilisation.